<DOC>
	<DOCNO>NCT01022112</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy , safety , tolerability TA-7284 compare placebo patient type 2 diabetes .</brief_summary>
	<brief_title>An Efficacy , Safety , Tolerability Study TA-7284 Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Type 2 diabetes mellitus ( T2DM ) well recognize major public health problem present patient significant risk complication include heart disease , retinopathy , nephropathy , neuropathy . Various class orally administer antihyperglycemic agent develop treatment T2DM although individual agent may highly effective patient , still difficult maintain optimal glycemic control patient , result high rate morbidity mortality diabetic population . This randomized , double-blind , placebo-controlled , parallel-group study demonstrate efficacy , safety , tolerability TA-7284 compare placebo patient T2DM , optimally control diet exercise . The primary study hypothesis study drug superior placebo assess change HbA1c baseline . The patient receive tablet TA-7284 , placebo , daily 12 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Aged 20 80 year inclusive day inform consent ; Patients diagnose type 2 diabetes mellitus least 3 month start runin period ; Patients HbA1c ≥6.5 % ≤9.5 % ( accord Japan Diabetic Society [ JDS ] criterion ) start day runin period ; Type I diabetes mellitus , diabetes mellitus result pancreatic disorder , secondary diabetes mellitus ( acromegaly , Cushing 's syndrome , etc . ) ; Past current history severe diabetic complication ( proliferative diabetic retinopathy , stage III later stage overt nephropathy , diabetic ketoacidosis , serious diabetic neuropathy ) ; Fasting blood glucose &gt; 270 mg/dL start day runin period Week 2 runin period ; eGFR &lt; 60 mL/min/1.73 m2 start day runin period ; Systolic blood pressure ≥160 mmHg diastolic blood pressure ≥100 mmHg start end day runin period ; History myocardial infarction , unstable angina , cerebrovascular disorder within 3 month start runin period ; Concurrent serious ( e.g. , require inpatient hospitalization surgical intervention ) renal hepatic disease ; Past current history malignant tumor ; however , criterion shall apply free relapse least 5 year even history malignant tumor . Past current history drug hypersensitivity shock anaphylactoid symptom ; Pregnant woman , lactate mother , woman childbearing potential ; Any condition subject assess ineligible investigator ( sub investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>TA-7284</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Sodium Glucose Co-transporter ( SGLT2 inhibitor )</keyword>
</DOC>